Open | 0.15 |
Previous Close | 0.1482 |
Day Range | 0.15 - 0.16 |
52-Week Range | 0.14 - 1.74 |
All-Time High | 10.32 |
Avg. Volume (50-day) | 6,458,096.5 |
EPS (TTM) | -0.6237 |
Next Earnings Date | 2025-05-08 (AMC) |
Last Earnings Date | 2025-03-13 |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.2400 |
PEG Ratio | - |
Price to Book | 0.74 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | - |
Revenue per Share (TTM) | - |
Shares Outstanding | 81.259 M |
Share Float (%) | 64.72 M |
% Held by Institutions | 30.34 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 0.19 (-21.11%) |
+/- SMA(50) | 0.24 (-37.54%) |
+/- SMA(200) | 0.4 (-62.52%) |
5-Day Perf. | -13.2% |
1-Month Perf. | -39.29% |
3-Month Perf. | -52.05% |
6-Month Perf. | -33.44% |
YTD Perf. | -41.72% |
1-Year Perf. | -86.25% |
RSI(14) | 23.7 |
ATR(14) | 0.02 |
ADX(14) | 29.95 |
Beta (5Y) | - |
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
INAB has triggered the following predefined scans:
P&F Double Bottom Breakdown |
P&F Descending Triple Bottom Breakdown |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.